论文部分内容阅读
目的 探讨原发性肝癌新临床分期的可行性。方法 1990年 1月至 1998年 12月经手术治疗原发性肝癌 10 38例 ,将其中肝叶切除具有完整病理学资料的 5 0 4例分别按国际抗癌联盟的TNM分期及中国抗癌协会 1999年新的临床分期进行统计学分析 ,比较各期的生存率。结果 按TNM分期各期病例数分别为Ⅰ期 2 4例 (4 8% ) ,Ⅱ期 6 6例 (13 1% ) ,Ⅲ期 385例 (76 4% ) ,Ⅳa期 2 9例 (5 8% ) ;5年生存率分别为 79 2 % ,6 2 1% ,32 2 %及 0。按新临床分期Ⅰa期 2 7例 (5 4% )、Ⅰb期81例 (16 1% )、Ⅱa期 2 2 4例 (44 4% )、Ⅱb期 141例 (2 7 9% )、Ⅲa期 31例 (6 2 % ) ;各期 5年生存率分别为 70 3%、5 3 1%、40 2 %、2 2 7%及 0。结论 新分期与TNM分期在选择治疗方法 ,估计预后方面作用相同 ,且新分期较TNM分期更有利于临床应用 ,值得推广
Objective To explore the feasibility of new clinical staging of primary liver cancer. Methods From January 1990 to December 1998, 1038 cases of primary liver cancer were treated by surgery. Among them, 504 cases with complete pathological data of liver lobectomy were classified according to the TNM staging of the International Union Against Cancer and the Chinese Anticancer Association 1999. A new clinical stage was performed for statistical analysis to compare the survival rates in each period. Results The number of cases according to TNM staging was 24 in phase I (4 8%), 66 in phase II (13 1%), 385 in phase III (76 4%), and 29 in IVa phase (5 8). %) The 5-year survival rates were 79 2%, 6 2 1%, 32 2%, and 0. According to the new clinical stage Ia, 27 cases (54%), Ib stage, 81 cases (161%), IIa stage, 224 cases (44%), IIb stage, 141 cases (27,9%), stage IIIa Thirty-one patients (62%) had 5-year survival rates of 70 3%, 531%, 40 2%, 227%, and 0. Conclusions The new staging and TNM staging have the same effect on the choice of treatment method and prognosis, and the new staging is more conducive to clinical application than TNM staging. It is worth promoting.